Inovio Pharmaceuticals Inc (INO) FinancialsINOInovio Pharmaceuticals Inc

Evaluating the bottom line, Inovio Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -409.87%, provide a clear picture of how effectively INO converts its operational activities into shareholder value.

In the context of the broader market, INO competes directly with industry leaders such as GNLX and VTVT. With a market capitalization of $118.91M, it holds a significant position in the sector. When comparing efficiency, INO's gross margin of N/A stands against GNLX's N/A and VTVT's 100.00%. Such benchmarking helps identify whether Inovio Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Inovio reported a gross margin of 100% in Q4 2024, but has since struggled with significant net losses, including a net income loss of $19,682,798 in Q1 2026. The company has a forward P/E ratio of 16.58, indicating potential future profitability but currently lacks revenue in recent quarters.